Rimexolone

Inquiry

Cat Number

API49697383

CAS Number

49697-38-3

If you have any other questions, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

49697-38-3

Synonyms

(11b,16a,17b)-11-Hydroxy-16,17-dimethyl-17-(1-oxopropyl)androsta-1,4-dien-3-one

Molecular Formula

C24H34O3

Molecular Weight

370.5

Smiles

CCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C)C

Melting Point

258-268℃

Boiling Point

507℃

Relative Density

1.12

pKa

14.42

General Description

Rimexolone is a synthetic glucocorticoid with high receptor affinity, developed specifically for ophthalmic use. Its unique structure — a 16α-methyl, 17α-propyl, and 21-nor configuration — confers potent anti-inflammatory activity in ocular tissues while promoting rapid systemic metabolism, minimizing systemic glucocorticoid exposure.

Mechanism of Action

Rimexolone binds to intracellular glucocorticoid receptors in ocular tissues and modulates the transcription of inflammatory genes, suppressing phospholipase A2 activity, prostaglandin and leukotriene synthesis, and cytokine production. Its rapid systemic metabolism prevents significant systemic corticosteroid effects.

Application

Indicated for the treatment of ocular inflammation including postoperative anterior uveitis and conjunctivitis. Rimexolone is a glucocorticoid specifically developed for ophthalmic use with a unique 21-nor steroid structure that provides potent local anti-inflammatory activity while promoting rapid systemic metabolism to minimize HPA axis suppression.

Rimexolone inhibited the proliferation of isolated human CD4+ T-cells stimulated with anti-CD3/anti-CD28 in a concentration-dependent manner. At 10⁻⁵ M, rimexolone significantly reduced the percentage of dividing cells. The production of IL-2 and other cytokines was also suppressed at this concentration. All inhibitory effects on proliferation and CD4 expression were blocked by the glucocorticoid antagonist RU486 and were not attributable to glucocorticoid-induced apoptosis. Rimexolone impaired T-cell signalling pathways through rapid non-genomic suppression of Akt, p38 and ERK phosphorylation. The inhibitory effects predominantly occurred at high concentrations, requiring a high occupation rate of cytosolic glucocorticoid receptors, with receptor-mediated non-genomic effects also contributing. These immunomodulatory effects explain the anti-inflammatory activity of rimexolone in local glucocorticoid therapy.

Fig. 1 Effects of Rimexolone at different concentrations on CD4 expression of unstimulated CD4+ T-cells (A and B) and CD4+ T-cells stimulated with aCD3/aCD28 (C and D). (Spies C M.; et al. 2010)

References

Spies C M, et al. Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells. Immunology letters, 2010, 131(1): 24-32.

What makes Rimexolone suitable for ophthalmic applications?

Rimexolone's unique 21-nor structure promotes rapid systemic inactivation after ocular absorption, limiting HPA axis suppression while maintaining potent local anti-inflammatory activity.

What purity grade is available?

Supplied as a high-purity grade suitable for ophthalmic R&D and pharmaceutical manufacturing.

Can packaging be customized?

Packaging formats and order quantities are customizable upon request for R&D and production needs.

Is international shipping available?

Available for supply to customers in most countries and regions worldwide.